A mouse radiation‐induced liver disease model for stereotactic body radiation therapy validated in patients with hepatocellular carcinoma. Issue 7 (21st June 2016)

• Record Type: Journal Article
• Authors: Wu, Zhi‐Feng; Zhang, Jian‐Ying; Shen, Xiao‐Yun; Zhou, Le‐Yuan; Gao, Ya‐Bo; Hu, Yong; Zeng, Zhao‐Chong
• Is Part Of: Medical physics. Volume 43:Issue 7(2016)
• Page Start: 4349
• Page End: 4361
• Publication Date: 2016-06-21
• Subjects: cancer -- dosimetry -- enzymes -- liver -- molecular biophysics -- radiation therapy; Therapeutic applications, including brachytherapy -- Cancer -- Biomolecules: structure and physical properties -- Dosimetry/exposure assessment -- Enzymes; Radiation therapy -- Scintigraphy; hepatocellular carcinoma -- radiation‐induced liver disease -- SBRT -- dose constraints; Dosimetry -- Liver -- Tissues -- Radiation treatment -- Cancer -- Lungs -- Kidneys -- Tissue engineering; Medical physics -- Periodicals; Medical physics; Geneeskunde; Natuurkunde; Toepassingen; Biophysics; Periodicals; Periodicals; Electronic journals; 610.153
• DOI: 10.1118/1.4953831
• Languages: English
• ISSNs: 0094-2405

Abstract

Abstract : Purpose: Lower radiation tolerance of the whole liver hinders dose escalations of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC) treatment. This study was conducted to define the exact doses that result in radiation‐induced liver disease (RILD) as well as to determine dose constraints for the critical organs at risk (OARs) in mice; these parameters are still undefined in HCC SBRT. Methods: This study consisted of two phases. In the primary phase, mice treated with helical tomotherapy‐based SBRT were stratified according to escalating radiation doses to the livers. The pathological differences, signs [such as mouse performance status (MPS)], and serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/albumin levels were observed. Radiation‐induced disease severities of the OARs were scored using systematic evaluation standards. In the validation phase in humans, 13 patients with HCC who had undergone radiotherapy before hepatectomy were enrolled to validate RILD pathological changes in a mouse study. Results: The evaluation criteria of the mouse liver radiotherapy‐related signs were as follows: MPS ≥ 2.0 ± 0.52, AST/ALT ≥ 589.2 ± 118.5/137.4 ± 15.3 U/L, serum albumin ≤ 16.8 ± 2.29 g/L. The preliminary dose constraints of the OARs were also obtained, such as those for the liver (average dose ≤ 26.36 ± 1.71 Gy) and gastrointestinal tract (maximum dose ≤ 22.63 Gy). Mouse RILD models were able to be developed when the livers were irradiated with average doses of ≥31.76 ± 1.94 Gy (single fraction). RILD pathological changes in mice have also been validated in HCC patients. Conclusions: Mouse RILD models could be developed with SBRT based on the dose constraints for the OARs and evaluation criteria of mouse liver radiotherapy‐related signs, and the authors' results favor the study of further approaches to treat HCC with SBRT.